Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAT2203 vs Fluconazole in VVC
NCT02971007Phase 2Completed
- Sponsor
- Matinas BioPharma
- Start
- Nov 2016
- Primary completion
- May 2017
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MAT2203 in vulvovaginal candidiasis (VVC), sponsored by Matinas BioPharma. Started Nov 2016; status: completed.
02
Drugs
MAT2203
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT02971007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971007.